GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,708.60p
   
  • Change Today:
      3.40p
  • 52 Week High: 1,713.00
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 7,547,306
  • Market Cap: £70,819m
  • RiskGrade: 129

GSK to produce 1bn doses of vaccine boosters

By Caoimhe Toman

Date: Thursday 28 May 2020

LONDON (ShareCast) - (Sharecast News) - Pharmaceutical company GlaxoSmithKline announced it will produce 1bn doses of coronavirus vaccine booster in preparation for an eventual immunisation drive.
GSK said its adjuvant could make "a significant contribution against Covid-19".

The company said it was in talks with governments to back the expansion of its manufacturing capabilities and that production would take place at sites in Europe and North America.

"As demonstrated in the last flu pandemic, GSK's pandemic adjuvant can reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people," GSK said according to the FT. "Additionally, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections."

The pharmaceutical industry is still racing to produce viable vaccine candidates to fight Covid-19.

Roger Connor, president of GSK's global vaccines division, said more than one vaccine would be needed to address the pandemic.

GSK is currently working with Sanofi on a vaccine candidate.

The company's stock was up 1.26% on Thursday, trading at 1,669p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,708.60p
Change Today 3.40p
% Change 0.20 %
52 Week High 1,713.00
52 Week Low 1,316.00
Volume 7,547,306
Shares Issued 4,144.88m
Market Cap £70,819m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average
55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average
Price Trend
50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average
29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average

What The Brokers Say

Strong Buy 7
Buy 6
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 28-Mar-2024

Time Volume / Share Price
17:14 750,000 @ 1,709.81p
17:04 13,917 @ 1,706.01p
17:04 13,076 @ 1,706.01p
17:04 549 @ 1,706.01p
17:03 172,458 @ 1,706.01p

GSK Key Personnel

CEO Emma Walmsley

Top of Page